[go: up one dir, main page]

WO2019051122A3 - CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS - Google Patents

CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS Download PDF

Info

Publication number
WO2019051122A3
WO2019051122A3 PCT/US2018/049798 US2018049798W WO2019051122A3 WO 2019051122 A3 WO2019051122 A3 WO 2019051122A3 US 2018049798 W US2018049798 W US 2018049798W WO 2019051122 A3 WO2019051122 A3 WO 2019051122A3
Authority
WO
WIPO (PCT)
Prior art keywords
regions
binding moieties
moieties containing
activated binding
conditionally activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/049798
Other languages
French (fr)
Other versions
WO2019051122A2 (en
Inventor
Robert B. Dubridge
Anand PANCHAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maverick Therapeutics Inc
Original Assignee
Maverick Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maverick Therapeutics Inc filed Critical Maverick Therapeutics Inc
Priority to JP2020513722A priority Critical patent/JP2020534811A/en
Priority to CN201880072457.XA priority patent/CN111315773A/en
Priority to EP18782834.8A priority patent/EP3679068A2/en
Publication of WO2019051122A2 publication Critical patent/WO2019051122A2/en
Publication of WO2019051122A3 publication Critical patent/WO2019051122A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des compositions de protéines de liaison à activation conditionnelle contenant des régions Fc, et des procédés de coexpression et de purification de telles protéines de liaison à activation conditionnelle. L'invention concerne également des méthodes de traitement du cancer par l'administration des protéines de liaison à activation conditionnelle à un patient.Provided are conditional activation binding protein compositions containing Fc regions, and methods for coexpressing and purifying such conditional activation binding proteins. The invention also relates to methods of treating cancer by administering conditional activation binding proteins to a patient.

PCT/US2018/049798 2017-09-08 2018-09-06 CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS Ceased WO2019051122A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2020513722A JP2020534811A (en) 2017-09-08 2018-09-06 Conditionally activated binding moiety containing the Fc region
CN201880072457.XA CN111315773A (en) 2017-09-08 2018-09-06 Conditionally active binding moieties comprising an Fc region
EP18782834.8A EP3679068A2 (en) 2017-09-08 2018-09-06 CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762555999P 2017-09-08 2017-09-08
US201762555943P 2017-09-08 2017-09-08
US62/555,943 2017-09-08
US62/555,999 2017-09-08

Publications (2)

Publication Number Publication Date
WO2019051122A2 WO2019051122A2 (en) 2019-03-14
WO2019051122A3 true WO2019051122A3 (en) 2019-04-11

Family

ID=63788012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/049798 Ceased WO2019051122A2 (en) 2017-09-08 2018-09-06 CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS

Country Status (4)

Country Link
EP (1) EP3679068A2 (en)
JP (1) JP2020534811A (en)
CN (1) CN111315773A (en)
WO (1) WO2019051122A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
MX2020002667A (en) 2017-09-08 2020-08-03 Maverick Therapeutics Inc Constrained conditionally activated binding proteins.
JP2021533744A (en) 2018-08-09 2021-12-09 マベリック セラピューティクス, インコーポレイテッドMaverick Therapeutics, Inc. Methods for co-expressing and purifying conditionally activated binding proteins
CN120484127A (en) 2019-03-05 2025-08-15 武田药品工业有限公司 Constrained conditionally active binding proteins
CN114173876A (en) * 2019-03-05 2022-03-11 武田药品工业有限公司 Conditionally active binding proteins containing Fc regions and moieties targeting tumor antigens
EP3969035A4 (en) * 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION CHARACTERISTIC GROUPS, ASSOCIATED PROCESSES AND USE
WO2021097376A1 (en) 2019-11-14 2021-05-20 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2022006562A1 (en) 2020-07-03 2022-01-06 Dana-Farber Cancer Institute, Inc. Multispecific coronavirus antibodies
US20230312715A1 (en) * 2020-09-04 2023-10-05 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding protein constructs with human serum albumin domains
US20240262917A1 (en) 2021-05-06 2024-08-08 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
WO2023034288A1 (en) 2021-08-31 2023-03-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for treatment of autoimmune disorders and cancer
AU2022396272A1 (en) 2021-11-24 2024-06-06 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
US20250051755A1 (en) 2021-12-17 2025-02-13 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
CA3241395A1 (en) 2021-12-17 2023-06-22 Barbel SCHROFELBAUER Antibodies and uses thereof
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
JP2025528835A (en) 2022-08-15 2025-09-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Antibodies to MSLN and methods of use thereof
CN117299082A (en) * 2023-08-18 2023-12-29 山西新华防化装备研究院有限公司 Preparation and evaluation method of nitrogen-doped renewable adsorption CNCL material

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119567A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2016046778A2 (en) * 2014-09-25 2016-03-31 Amgen Inc Protease-activatable bispecific proteins
WO2016179285A1 (en) * 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
WO2016187594A1 (en) * 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2017156178A1 (en) * 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Inducible binding proteins and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
DE69233013T2 (en) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer ADENOVIRUS MEDIATED GENTRANSFER INTO THE GASTROINTESTINAL TRACT
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
JP3532566B2 (en) 1993-06-24 2004-05-31 エル． グラハム，フランク Adenovirus vectors for gene therapy
JP3875990B2 (en) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド Recombinant adenoviral vectors and methods of use
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2003512821A (en) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド Methods for regulating transcription of exogenous genes
DE10231109A1 (en) 2002-07-10 2004-01-22 Daimlerchrysler Ag exhaust turbine
SG11201508231UA (en) * 2013-04-19 2015-11-27 Covagen Ag Novel bispecific binding molecules with antitumoral activity
CN106632681B (en) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 Anti- EGFR and AntiCD3 McAb bispecific antibody and its application

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119567A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2016046778A2 (en) * 2014-09-25 2016-03-31 Amgen Inc Protease-activatable bispecific proteins
WO2016179285A1 (en) * 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
WO2016187594A1 (en) * 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2017156178A1 (en) * 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Inducible binding proteins and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAD MAY ET AL: "Advances in bispecific biotherapeutics for the treatment of cancer", BIOCHEMICAL PHARMACOLOGY, vol. 84, no. 9, 1 November 2012 (2012-11-01), pages 1105 - 1112, XP055071310, ISSN: 0006-2952, DOI: 10.1016/j.bcp.2012.07.011 *
FRANKEL STANLEY R ET AL: "Targeting T cells to tumor cells using bispecific antibodies", ENGINEERED PROTEIN SCAFFOLDS AS NEXT-GENERATION ANTIBODY THERAPEUTICS,, vol. 17, no. 3, 1 June 2013 (2013-06-01), pages 385 - 392, XP002787546, ISSN: 1879-0402 *

Also Published As

Publication number Publication date
EP3679068A2 (en) 2020-07-15
WO2019051122A2 (en) 2019-03-14
CN111315773A (en) 2020-06-19
JP2020534811A (en) 2020-12-03

Similar Documents

Publication Publication Date Title
WO2019051122A3 (en) CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS
WO2019195810A3 (en) Atf6 inhibitors and uses thereof
EA200800564A1 (en) DERIVATIVES OF XANTHINE AS SELECTIVE AGONISTS NM74A
WO2007138116A3 (en) Pharmaceutical composition for the treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein breakdown
UA106079C2 (en) Normal;heading 1;heading 2;heading 3;APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES
ATE442142T1 (en) FREDERICAMYCIN DERIVATIVES AS DRUGS FOR TUMOR TREATMENT
UA108193C2 (en) APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES
EA200801163A1 (en) PROTEIN INHIBITORS ACTIVATING 5-LIPOXYENASE (FLAP)
EA200801164A2 (en) PROTEIN INHIBITORS ACTIVATING 5-LIPOXYENASE (FLAP)
EA200801580A1 (en) NEW PIRININOD DERIVATIVES AND METHOD FOR THEIR PRODUCTION
MA40768B1 (en) Mono or di-substituted indole derivatives as dengue virus replication inhibitors
EA200601212A1 (en) PHOSPHODESTERASE INHIBITORS, OBTAINING AND THEIR THERAPEUTIC APPLICATION
JP2015529685A5 (en)
EP4596048A3 (en) Cd73 inhibitors
WO2021239935A9 (en) Neutralizing antibodies against sars-related coronavirus
ES2119185T3 (en) TREATMENT OF MICOBACTERIAL DISEASES BY ADMINISTRATION OF BACTERICIDE PROTEIN PRODUCTS / INCREASES PERMEABILITY.
MX2021006253A (en) Gene therapies for neurodegenerative disease.
Garcia-Garrote et al. Interaction between angiotensin type 1, type 2, and Mas receptors to regulate adult neurogenesis in the brain ventricular–subventricular zone
WO2021107656A3 (en) Novel quercetin redox derivative and use thereof as bet inhibitor
WO2020142740A8 (en) Treatment of sjogren's disease with nuclease fusion proteins
AU2012280776B2 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
TW200628473A (en) Novel heterocycles
WO2020163493A3 (en) Materials and methods for treating a neurodegenerative disease
MX2025008431A (en) Il-12 fc fusion proteins
TW200719903A (en) Compositions for the treatment of neoplasms

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18782834

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020513722

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018782834

Country of ref document: EP

Effective date: 20200408